Texas Capital Bank Wealth Management Services Inc Acquires Shares of 3,416 Astrazeneca Plc $AZN

Texas Capital Bank Wealth Management Services Inc purchased a new position in shares of Astrazeneca Plc (NYSE:AZN) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 3,416 shares of the company’s stock, valued at approximately $600,000.

Several other institutional investors have also modified their holdings of the stock. Bank of America Corp DE raised its holdings in shares of Astrazeneca by 4.7% during the 3rd quarter. Bank of America Corp DE now owns 32,633,139 shares of the company’s stock worth $2,503,614,000 after acquiring an additional 1,461,786 shares during the period. Fisher Asset Management LLC raised its holdings in shares of Astrazeneca by 2.1% during the 4th quarter. Fisher Asset Management LLC now owns 21,601,433 shares of the company’s stock worth $3,791,051,000 after acquiring an additional 438,709 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Astrazeneca by 9.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 6,805,896 shares of the company’s stock worth $521,517,000 after acquiring an additional 582,183 shares during the period. Holocene Advisors LP raised its holdings in shares of Astrazeneca by 41.8% during the 3rd quarter. Holocene Advisors LP now owns 6,129,194 shares of the company’s stock worth $470,232,000 after acquiring an additional 1,807,565 shares during the period. Finally, Ameriprise Financial Inc. raised its holdings in shares of Astrazeneca by 13.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 5,707,561 shares of the company’s stock worth $438,342,000 after acquiring an additional 660,569 shares during the period. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Astrazeneca Price Performance

Astrazeneca stock opened at $185.66 on Friday. The company’s 50 day simple moving average is $191.34 and its 200-day simple moving average is $183.64. The company has a market capitalization of $287.94 billion, a price-to-earnings ratio of 27.88, a price-to-earnings-growth ratio of 1.48 and a beta of 0.26. Astrazeneca Plc has a 1 year low of $137.23 and a 1 year high of $212.71. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91.

Astrazeneca (NYSE:AZN) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. The business had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. As a group, equities research analysts expect that Astrazeneca Plc will post 10.26 earnings per share for the current year.

Analysts Set New Price Targets

AZN has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Astrazeneca in a report on Thursday, May 21st. Morgan Stanley reiterated an “overweight” rating on shares of Astrazeneca in a report on Wednesday, April 8th. Jefferies Financial Group reiterated a “buy” rating on shares of Astrazeneca in a report on Wednesday, May 13th. Wall Street Zen raised shares of Astrazeneca from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Finally, UBS Group reissued a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. Twelve equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.